Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 17/20 | 1.00 |
| ▸ | THRA | P10827 | 16/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14627902 | 0.82 | THRB (0.74) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL2920575 | 0.80 | THRB (0.70) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL2920565 | 0.80 | THRA (1.00) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL25874297 | 0.79 | THRB (0.69) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL2924045 | 0.79 | THRA (1.00) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL2921624 | 0.79 | THRB (0.66) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL2926087 | 0.78 | THRB (0.64) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL2921871 | 0.77 | THRA (0.62) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL38650559 | 0.77 | THRA (0.62) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL13116434 | 0.76 | THRB (0.72) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919878-B1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-08 | — | — | EP | claimed |
| EP-1919878-A1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | F. Hoffmann-Roche AG (CH) | 2008-05-14 | — | — | EP | claimed |
| WO-2007009913-A1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | claimed |
| US-RE46024-E1 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-RE46024-E1 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-RE46024-E1 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-7807674-B2 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807674-B2 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807674-B2 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1919878-B1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-08 | — | — | EP | disclosed |
| EP-1919878-B1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-08 | — | — | EP | disclosed |
| US-7452882-B2 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452882-B2 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452882-B2 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1919878-A1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | F. Hoffmann-Roche AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20070032494-A1 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032494-A1 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032494-A1 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007009913-A1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009913-A1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032494-A1 | Thyroid hormone analogs | THRA, THRB, TPO | THRB 2/4885THRA 1/4885CYP2C9 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.